检索结果-南通市图书馆

Incidence,Survival Outcome,and Prognostic Nomogram of Patients with Angioimmunoblastic T-cell Lymphoma:a Population-based Analysis

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Current Medical Science 2022年第6期42卷 1220-1230页

作者： Hai-zhu CHEN Yun-xia TAO Yu ZHOU Qiao-feng ZHONG Li-qiang ZHOU yuan-kai shi Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeBeijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted DrugsBeijing100021China

Objective Due to the rarity of angioimmunoblastic T-cell lymphoma(AITL),very limited data concerning its incidence patterns and prognostic factors are *** study aimed to explore the incidence,characteristics,survival outcomes,and prognostic factors of *** Age-adjusted incidence and temporal trends were calculated based on 1247 AITL patients from the National Cancer Institute’s Surveillance,Epidemiology,and End Results(SEER)-13 database.A total of 1525 AITL patients from the SEER-18 database and 43 patients from our single center were included for survival analysis and nomogram *** The age-adjusted incidence for overall cohort was 0.123[95%confidence interval(CI),0.117–0.131)per 100000 during 1992–*** overall incidence increased steeply at the rate of 15.3%(95%CI 11.0%–19.8%,P<0.001)per year during 1992–2004,but remained stable during 2004–2017(P=0.200).Similar incidence trends were observed in age,sex,and stage *** final nomograms consisted of four variables:age at diagnosis,sex,Ann Arbor stage,and primary *** concordance index(C-index)of the nomogram for 5-year overall survival prediction was 0.717,0.690 and 0.820 in the training cohort,validation cohort-1 and cohort-2,*** the disease-specific survival(DSS),the nomogram also demonstrated a good discrimination level,with the C-index for predicting the probability of DSS at 5 years of 0.716,0.682 and 0.813 for the three cohorts,*** calibration displayed good concordance between the nomogram-predicted and actual observed *** The age-adjusted incidence for AITL was low during 1992–*** incidence continuously increased during 1992–2004,but remained stable during 2004–*** nomograms as proposed may provide a favorable and accurate prognostic survival prediction in AITL.

关键词： angioimmunoblastic T-cell lymphoma incidence prognosis nomogram SEER

A case of locally advanced gastric cancer treated with nivolumab, trastuzumab, plus chemotherapy in a neoadjuvant setting

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Medical Journal 2019年第11期132卷 1370-1371页

作者： shi-Yu Jiang Yan Qin yuan-kai shi Department of Medical Oncology Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing 100021 China

To the Editor:Recently,the advantages of peri-operative chemotherapy in downstaging tumor and improving patient survival have been reported. Herein, we report a case of gastric cancer patient receiving neoadjuvant che... 详细信息

关键词： chemotherapy Gastric cancer patients tumor

Impaired Erythropoietin Response to Anemia in Patients with Lymphocytic Malignancies

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Sciences Journal 2007年第3期22卷 203-204页

作者： Bing Han yuan-kai shi Jun Zhu Xiao-hui He Ning-jing Lin Shu-lan Li Ti Shen Department of Hematology Peking Union Medical College Hospital Chinese Academy of Medical Sciences ＆Peking Union Medical College Beijing 100730 Department of Medical Oncology Cancer Hospital Chinese Academy of Medical Sciences ＆ Peking Union Medical College Beijing 100021 Department of Medical Oncology Peking University School of Oncology ＆ Beijing Cancer Hospital Beijing 100036

Patients with lymphocytic malignancies like Non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), and chronic lymphocytic leukemia (CLL) are often complicated with anemia. In this prospective study, we devised a carefully controlled erythropoietin (Epo) level measurement in anemic or non-anemic patients with lymphocytic malignancies, in order to determine whether the response of Epo was decreased in anemic patients.

关键词：促红细胞生成素淋巴细胞贫血治疗

Complete response of gallbladder cancer treated with gemcitabine and cisplatin chemotherapy combined with durvalumab:A case report and review of literature

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastrointestinal Oncology 2025年第1期17卷 226-232页

作者： kai Chen Xu Feng yuan shi Xin-Lin Li Zheng-Rong shi Xiang Lan Department of Hepatobiliary Surgery The First Affiliated Hospital of Chongqing Medical UniversityChongqing 400016China

BACKGROUND Gallbladder cancer(GBC)is the most common and aggressive subtype of biliary tract cancer(BTC)and has a poor prognosis.A newly developed regimen of gemcitabine,cisplatin,and durvalumab shows promise for the treatment of advanced ***,the efficacy of this treatment for GBC remains *** SUMMARY In this report,we present a case in which the triple-drug regimen exhibited marked effectiveness in treating locally advanced GBC,thus leading to a long-term survival benefit.A 68-year-old man was diagnosed with locally advanced GBC,which rendered him ineligible for curative *** three cycles of therapy,a partial response was *** one year of combined therapy,a clinical complete response was successfully *** maintenance therapy with durvalumab monotherapy resulted in a disease-free survival of 9 months for the *** patient experienced tolerable toxicities of reversible grade 2 nausea and *** adverse events were observed in the patient throughout the entirety of the *** The combination of gemcitabine and cisplatin chemotherapy with durvalumab was proven to be an effective treatment approach for advanced GBC,with manageable adverse *** research is warranted to substantiate the effectiveness of the combined regimen in the context of GBC.

关键词： Gallbladder cancer Chemotherapy Immunotherapy Durvalumab Complete response Case report

Efficacy and safety of albumin-bound paclitaxel in treating recurrent advanced non-small-cell lung cancer

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Journal of Cancer Research 2013年第2期25卷 200-205页

作者： Pu-yuan Xing Jun-Ling Li Yan Wang Xue-Zhi Hao Bin Wang Lin Yang yuan-kai shi Xiang-Ru Zhang Cancer Institute and Hospital Chinese Academy of Medical Sciences & Peking Union Medical College

Objective： To observe the efficacy and safety of albumin-bound paclitaxel （ABP） monotherapy in treating recurrent advanced non-small-cell lung cancer （NSCLC）. Methods： We retrospectively analyzed the short-term efficacy and toxicities of ABP monotherapy in treating 21 patients who had previously undergone multiple cycles of therapy for their advanced NSCLC in our hospital since 2010. The treatment-related survival was also analyzed. Results： Of these 21 patients, the best overall response was partial response （PR） in 6 patients （28.6%）, stable disease （SD） in I0 patients （47.6%）, and progressive disease （PD） in 5 patients （23.8%）. The overall response rate （ORR） was 28.6% and the disease control rate （DCR）（PR ＋ SD） was 76.2%. The median progression-flee survival （PFS） was 4.0 months （95% CI, 5.0-7.0 months）. The main grade 3/4 toxicities included neutropenia （11.1%）, peripheral nerve toxicity （5.6%）, muscle and joint aches （5.6%）, and fatigue （5.6%）. Conclusions： The ABP monotherapy can achieve good objective response in advanced NSCLC patients who have previously received multiple cycles of treatment and be well tolerated.

关键词： Albumin-bound paclitaxel paclitaxel advanced non-small cell lung cancer chemotherapy

A retrospective analysis of real-world outcomes of elderly Chinese patients with diffuse large B-cell lymphoma

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 2019年第15期132卷 1807-1814页

作者： Peng Liu Ying Han shi-Yu Jiang Xiao-Hui He Yan Qin Lin Gui Sheng-Yu Zhou Li-Qiang Zhou Jian-Liang Yang Sheng Yang Ting-Yu Wen yuan-kai shi Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs Beijing 100021 China

Background:Elderly patents with diffuse large B-cell lymphoma (DLBCL) have a worse prognosis than younger patients,and the optimal treatment strategy for this group remains *** conducted a retrospective analysis to investigate the clinical features and outcomes of elderly patients (>60 years) and to assess the impact of clinical and molecular factors on outcome in this age ***:From April 2006 to December 2012,a total of 349 elderly patients with DLBCL from the National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences,and Peking Union Medical College were included in this *** were further divided into two age groups (61-69 years and ≥70 years).We compared clinical characteristics and outcomes between ***:Of 349 total patients,204 (58.5%) were aged 61 to 69 years,and 145 (41.5%) patients were aged 70 years or *** for the Eastern Cooperative Oncology Group performance status,clinical characteristics were comparable between the two *** a median follow-up of 82 (range,1-129) months,the 5-year overall survival (OS) and progression-free survival (PFS) rates were 51.9% and 45.8%,*** 5-year OS rates for patients aged 61 to 69 years and those over 70 years were 58.3% and 42.8%(P =0.007),respectively,and the 5-year PFS rates were 51.0% and 38.6%(P =0.034).Treatment regimens including rituximab provided a higher 5-year OS rate (63.1% vs.37.1%,P < 0.001) and PFS rate (56.6% vs.31.8%,P < 0.001) than chemotherapy *** patients aged 61 to 69 years,chemotherapy plus rituximab resulted in a higher 5-year OS rate (66.7% vs.46.4%,P =0.002) and PFS rate (60.0% vs.38.1%,P =0.002) than chemotherapy *** patients aged ≥70 years,there was a marked survival advantage in patients who received chemotherapy plus rituximab (5-year OS rate:57.7% vs.25.4%,P < 0.001;5-year PFS rate:51.3% vs.23.9%,P < 0.001) compared with that seen in those who received chemotherapy *** analysis es

关键词： Elderly Diffuse large B-cell lymphoma Rituximab Prognosis

Decreased Prognostic Value of International Prognostic Score in Chinese Advanced Hodgkin Lymphoma Patients Treated in the Contemporary Era

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 2016年第23期129卷 2780-2785页

作者： Qin Wang Yan Qin Su-Yi Kang Xiao-Hui He Peng Liu Sheng Yang Sheng-Yu Zhou Chang-Gong Zhang Lin Gui Jian-Liang Yang Yan Sun yuan-kai shi Department of Medical Oncology Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs National Cancer Center/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100021 China

Background： The International Prognostic Score （IPS） was developed based on the data of Western advanced Hodgkin lymphoma （HL） patients treated before 1992. Only a few studies ever evaluated the application value of IPS in Chinese population or in patients treated in the contemporary era whose outcomes has improved significantly than before. Methods： We conducted a retrospective study involving 208 previously untreated Chinese advanced HL patients, who were admitted to Cancer Hospital Chinese Academy of Medical Sciences from January 1, 1999 to April 30, 2015 and received uniform first-line treatment. The prognostic value of both IPS and the seven IPS factors for freedom-from progression （FFP） and overall survival （OS） was assessed in this population. The statistical methods included Kaplan-Meier methodology, log-rank testing, and Cox proportional hazard regression analysis. Results： With a median follow-up time of 79 months （range, 15-210 months）, the 5-year FFP and OS were 78.8% and 86.0% respectively, which improved obviously compared with the original IPS study. The IPS remained prognostic for both FFP （P = 0.041 ） and OS （P = 0.013）, but the range narrowed obviously, with 5-year FFP ranging from 87.2% to 61.5%, 5-year OS ranging from 94.1% to 69.2%, and the separation of survival curves was not as good as before. Only two of the seven IPS factors showed a significant independent prognostic value in the multivariate analysis： Stage IV （for FFP, hazard ratio [HR] = 2.219, 95% confidence interval [CI]： 1.148-3.948, P = 0.016; for OS, HR = 2.491, 95% CI： 1.159-5.355, P = 0.019） and hemoglobin 〈105 g/L （for FFP, HR = 2.136, 95% CI： 1.123-4.060, P = 0.021; for OS, HR = 2.345, 95% CI： 1.099-5.042, P = 0.028）. A simple prognostic score calculated by adding one point each for any of the two factors was prognostic both for FFP （P 〈 0.001 ） and OS （P 〈 0.001 ） with the survival curves separating very well, but the range still narrowed. Conclusions： The IPS has decreased th

关键词： Hodgkin Lymphoma International Prognostic Score Prognosis

CHARACTERISTIC SPECTRUM RESEARCH IN AE SIGNALS BASED ON WAVELET ANALYSIS

在线全文

学校读者我要写书评

暂无评论

CHARACTERISTIC SPECTRUM RESEARCH IN AE SIGNALS BASED ON WAVE...

Efficacy of peripheral blood stem cell transplantation versus conventional chemotherapy on anaplastic large-cell lymphoma:a retrospective study of 64 patients from a single center

第三届全国压电和声波理论及器件技术研讨会

作者： Xiao-qing yuan,Yi-kai shi School of Mechatronics,Northwestern Polytechnical University,Xi’an,Shaanxi 710072,China

Acoustic emission(AE) signal is one kind of non-steady random signal,its frequency and the statistical nature change with the time *** traditional spectrum analysis,a spectrum can’t be used to determine what the corresponding period of time domain signal *** to Mallat decomposition algorithm,wavelet decomposition of each scale and structure is the convolution of a low-pass filter and a high-pass filter,acoustic emission signal is decomposed into different frequency range of time-domain signal *** lower-scale decomposition component gives expression to high-frequency of the local information,and the higher-scale decomposition component gives expression to low-frequency of the local information.A measured AE signal was decomposed by *** results showed that AE wave spectrum feature analysis based on wavelet analysis can be used to analyze the spectrum characteristics of the emission signal,and effectively extract useful information of AE.

关键词： Acoustic emission wavelet analysis spectral analysis

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

Chinese Journal of Cancer 2012年第11期31卷 532-540页

作者： Xiao-Hui He Bo Li Shuang-Mei Zou Mei Dong Sheng-Yu Zhou Jian-Liang Yang Li-Yan Xue Sheng Yang Peng Liu Yan Qin Chang-Gong Zhang Xiao-Hong Han yuan-kai shi Department of Medical Oncology Deparkment of Pathology Cancer Institute and HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021P.R.China.

Anaplastic large-cell lymphoma(ALCL) is characterized by frequently presenting adverse factors at *** groups believed aggressive treatment strategies such as autologous stem cell transplantation brought survival benefit for ALCL ***,few compared these approaches with conventional chemotherapy to validate their ***,we report a study comparing the efficacy of peripheral blood stem cell transplantation(PBSCT) and conventional chemotherapy on ALCL.A total of 64 patients with primary systemic ALCL were studied *** median follow-up period was 51 months(range,1-167 months).For 48 patients undergoing conventional chemotherapy only,the 4-year event-free survival(EFS) and overall survival(OS) rates were 70.7% and 88.3%,***,16 patients underwent PBSCT,including 11 at first remission(CR1/PR1),3 at second remission,and 2 with disease progression during first-line *** 4-year EFS and OS rates for patients underwent PBSCT at first remission were 81.8% and 90.9%,*** with conventional chemotherapy,PBSCT did not show superiority either in EFS(P = 0.240) or in OS(P = 0.580) when applied at first *** analysis showed that patients with B symptoms(P = 0.001),stage III/IV disease(P = 0.008),bulky disease(P = 0.075),negative anaplastic lymphoma kinase(ALK) expression(P = 0.059),and age ≤ 60 years(P = 0.054) had lower ***,PBSCT significantly improved EFS in patients with B symptoms(100% vs.50.8%,P = 0.027) or bulky disease(100% vs.52.8%,P = 0.045) when applied as an up-front *** on these results,we conclude that,for patients with specific adverse factors such as B symptoms and bulky disease,PBSCT was superior to conventional chemotherapy in terms of EFS.

关键词：造血干细胞移植疗效比较淋巴瘤外周血化疗变性 EFS 单因素分析